Pharma losing the battle over drug prices

World of DTC Marketing

According to the KFF poll “ most adults – across partisans – don’t believe high drug prices are needed for drug companies to invest in new research instead agreeing that “even if U.S. The post Pharma losing the battle over drug prices.

Drugs 165

The drug industry can’t fight change

World of DTC Marketing

While it’s true, the drug industry developed COVID vaccines; the government spent billions on research pre-pandemic and $18 billion more on trials, production, and purchase. Drug corps are reaping record profits. Drug companies should prepare for this scenario.

Drugs 203
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Drug companies know how to play the FDA drug approval process

World of DTC Marketing

SUMMARY: The FDA has many puzzled as to why they approve some drugs with questionable data and ask for more data on other drugs. The FDA approves drugs on the potential to save a life, the cost of the drugs is never considered in the process.

Drugs 161

Clinical trial DTC? It may not be right for your drug candidate

World of DTC Marketing

The FDA approved 309 new drugs between 2011 and 2018, 38 per year on average. In 2018, the FDA approved 59 new drugs – an all-time high. The industry loses an average of $40 billion per year on drug development, part of which is due to trial delays.

Open Source “Wikipedia” for Drug Discovery

Pharma Mirror

Open source drug discovery was proposed in the past in connection with third-world diseases like tuberculosis and malaria, but it is in the context of first-world indications where it is needed most. The post Open Source “Wikipedia” for Drug Discovery appeared first on Pharma Mirror Magazine.

Prescription drug prices are out of cotrol

World of DTC Marketing

This includes about one in five who report that they have not filled a prescription or took an over-the counter drug instead, and about one in ten who say they have cut pills in half or skipped a dose. Drug prices in the United States are extreme. Drug Prices

Drugs 157

Drug pricing increases are disgraceful

World of DTC Marketing

SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices

Drugs 158

Seagen, Genmab win speedy FDA approval for cervical cancer drug

Bio Pharma Dive

Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019

New cancer drug clinical trials struggling

World of DTC Marketing

This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials.

Um, about that diabetes drug that helped patients lose weight

World of DTC Marketing

Yet the media has led with “diabetes drug leads to major weight loss” Will doctors inform patients? The drug carries a potential risk for a type of thyroid tumor and has a boxed warning. This drug can be effective if patients follow the directions for weight loss.

Drugs 167

Incyte eczema drug wins FDA OK, but with safety warning

Bio Pharma Dive

A topical cream formulation of the drug in Incyte's top-selling product could help the company expand. The black box warning, though, might limit use

Pfizer stocks cancer drug pipeline with $2.3B deal for Trillium

Bio Pharma Dive

The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year

Otsuka partners with Sunovion, Sumitomo in neurology drug pact

Bio Pharma Dive

Sunovion will receive $270 million from Otsuka, and as much as $620 million more, in exchange for splitting rights to four experimental psychiatric drugs

Drugs 192

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. ” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science?

Drugs 161

With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt

Bio Pharma Dive

The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena

In first, FDA approves KRAS-blocking cancer drug from Amgen

Bio Pharma Dive

Lumakras is the first drug proven effective For decades, scientists have tried unsuccessfully to target the KRAS gene, which is often mutated in lung, colon and pancreatic cancers.

FDA approves Lilly, Boehringer diabetes drug for heart failure

Bio Pharma Dive

The expanded clearance in heart failure with reduced ejection fraction is expected to boost sales of the drug, called Jardiance

Takeda wins FDA approval for targeted lung cancer drug

Bio Pharma Dive

Unlike J&J's drug, however, Takeda's is given orally Exkivity follows Johnson & Johnson's Rybrevant on the market for treating lung tumors harboring specific mutations in the EGFR gene.

That $56,000 Drug? Blame Medicare.

NY Times

For an increasingly important set of drugs, Medicare has been driving up prices. Drugs (Pharmaceuticals) Health Insurance and Managed Care Prices (Fares, Fees and Rates) Medicare Elderly Biogen Inc Food and Drug Administration Aduhelm (Drug) Alzheimer's Disease

Drugs 66

The debate on DTC marketing is going to heat up again

World of DTC Marketing

SUMMARY: DTC marketing is not the reason why prescription drugs cost so much. They research the drug online and ask their physician about it if they decide it’s a treatment option. 2wo: DTC marketing is one of the reasons prescription drugs cost so much.

Social media and prescription drugs: A study

World of DTC Marketing

QUICK READ: A two-month analysis of social media and prescription drugs found the number one reason online health seekers use social media is to share and ask questions about medication side effects. The post <strong>Social media and prescription drugs:</strong> A study.

Drugs 235

Regeneron, AstraZeneca team up on targeted drugs for obesity

Bio Pharma Dive

AstraZeneca aims to help the biotech make a drug based on its findings After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight.

Drugs 227

Ohio Clinic Says It Won't Administer Alzheimer's Drug to Patients

NY Times

The rejection of the new Alzheimer’s drug by the two major medical centers is one of the starkest signs of concern over its approval by the F.D.A.

Drugs 87

Over-the-counter drug product monographs: What you need to know

Bio Pharma Dive

Register for our OTC-focused webinars to get a deeper look at five OTC drug monographs

FDA documents show how controversial Alzheimer's drug decision was reached

Bio Pharma Dive

A group of statisticians who had argued for rejection were overruled, internal memos show, as high-ranking agency officials got behind an accelerated clearance for Biogen's drug

Drugs 253

Prescription drug marketing misconceptions

World of DTC Marketing

Another TED talk on the evils of prescription drug marketing was filled with misinformation as usual. The disconnect between consumers and prescription drug marketing has grown quite a bit. The post Prescription drug marketing misconceptions appeared first on World of DTC Marketing.com.

Roche stops giving Huntington's disease drug in closely watched study

Bio Pharma Dive

A disappointing recommendation from outside data reviewers raises doubts about the DNA-targeting drug's benefits and puts pressure on Roche's partner, Ionis Pharmaceuticals

DNA 266

FDA grants approval to Ebola drug from Ridgeback

Bio Pharma Dive

In a landmark study, fewer people given Ebanga died from Ebola virus infection than did those who received a control drug. Results from the trial also led to an OK for Regeneron's drug Inmazeb

Trials 264

Launching a drug in a pandemic

World of DTC Marketing

QUICK READ : Prescribers are reviewing some of their favorite prescribed drugs and are open to learning about new drugs in terms of efficacy and patient outcomes but you had better be ready to talk about patients beyond the science.

Drugs 130

Pharma is “big business” that uses excuses to keep prices high

World of DTC Marketing

SUMMARY: Americans spend twice as much per capita on drugs as residents of other wealthy nations, because ours is the only country that lets drugmakers set any price they want for their products. Via Axios “The 10 highest-selling drugs in the U.S. in the news Price of Rx drugs

Sales 224

COVID-19 drug developer Adagio plans IPO to cap fast rise

Bio Pharma Dive

The offering is the latest step in the rapid emergence of Adagio, which raised nearly $400 million and brought a drug to pivotal testing in less than a year

How an Unproven Alzheimer’s Drug Got Approved

NY Times

Aduhelm (Drug) Alzheimer's Disease Food and Drug Administration Drugs (Pharmaceuticals) Labeling and Labels (Product) Clinical Trials Elderly Science and Technology Regulation and Deregulation of Industry Research Brain Biogen Inc your-feed-science your-feed-healthcare

Drugs 79

Amgen study data bolster prospects of KRAS-blocking cancer drug

Bio Pharma Dive

Results from a mid-stage study showed Amgen's drug, sotorasib, shrank tumors in over a third of lung cancer patients, affirming earlier findings

Drugs 257

The F.D.A.'s Approval of Biogen's Alzheimer's Drug Is a New Low

NY Times

s approval of the Alzheimer's drug aducanumab is inexplicable. . Drugs (Pharmaceuticals) Aduhelm (Drug) Alzheimer's Disease Food and Drug Administration Biogen IncThe F.D.A.'s

Drugs 78

Trial failure dashes Biogen hopes for next Alzheimer's drug

Bio Pharma Dive

Days after Aduhelm's approval, Biogen said an experimental drug that works in a different way didn't help patients, leading the company to stop research

Trials 208

GSK, Merck KGaA end cancer drug partnership after study results disappoint

Bio Pharma Dive

Bintrafusp alfa was highlighted by GSK as a potential blockbuster drug as recently as January. Negative findings in two trials, however, led the companies to unwind their research collaboration

Trials 207

Merck gives an early peek at COVID-19 drug results

Bio Pharma Dive

Initial results from a mid-stage study indicate the antiviral drug, molnupiravir, is safe. But whether it's hitting the study's main goal remains unclear

Drugs 241

Biogen Alzheimer's approval could open the door for other similar drugs

Bio Pharma Dive

Approval of Aduhelm sets a precedent that could enable some drugs, like Eli Lilly's drug donanemab, to advance quickly and cause other previously sidelined ones to get a second look

Drugs 253

Alzheimer’s Drug Poses a Dilemma for the F.D.A.

NY Times

Alzheimer's Disease Drugs (Pharmaceuticals) Clinical Trials Elderly Memory Brain Aducanumab (drug) Biogen Inc Food and Drug Administration Alzheimer's Assn your-feed-science your-feed-healthcare

F.D.A. Approves GHB, a ‘Date Rape’ Drug, for Rare Sleeping Disorder

NY Times

Drugs (Pharmaceuticals) Sedatives Narcolepsy Sleep Food and Drug Administration Jazz Pharmaceuticals Inc Drug Abuse and TrafficJazz Pharmaceuticals brought in more than $1.7 billion last year selling GHB to narcolepsy patients. With the new approval, sales could soar.

Sales 77

FDA Designations for Rare Disease Products, Part 2: Orphan Drug Designation

Camargo

The Camargo Blog is publishing a four-part blog series highlighting those designation programs available specifically for products with rare disease indications: Orphan Drug Designation (ODD), Rare Pediatric Disease Designation (RPDD), and Humanitarian Use Device (HUD) designation.

Celldex pins its hopes for a comeback on skin disease drug

Bio Pharma Dive

After several setbacks, most notably the failure of a brain cancer vaccine, Celldex has a chance at reinvention should early drug results pan out for the 16-year-old biotech

F.D.A. Requests Investigation of Its Own Alzheimer’s Drug Approval

NY Times

The agency’s acting head said a federal review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. Aduhelm (Drug) Alzheimer's Disease Drugs (Pharmaceuticals) Inspectors General Biogen Inc Food and Drug Administration Woodcock, Janet

Drugs 74